Clinical Trial Search Results for "PROVE IT-TIMI 22"

Cannon, C. P., McCabe, C. H., Belder, R., Breen, J., Braunwald, E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial Am J Cardiol. 2002;89(7):860-1.

Cannon, C. P. The next step in cardiovascular protection Atheroscler Suppl. 2003;4(5):9-Mar. Abstract

Cannon, C. P. PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome Crit Pathw Cardiol. 2003;2(3):188-96.

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.

Cannon, C. P., Braunwald, E., McCabe, C. H., Grayston, J. T., Muhlestein, B., Giugliano, R. P., Cairns, R., Skene, A. M. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome N Engl J Med. 2005;352(16):1646-54.

Ray, K. K., Cannon, C. P. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol. 2005;96(5A):54F-60F. Abstract

Ray, K. K., Cannon, C. P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes J Am Coll Cardiol. 2005;46(8):1425-33. Abstract

Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Rifai, N., Kirtane, A. J., McCabe, C. H., Skene, A. M., Gibson, C. M., Ridker, P. M., Braunwald, E. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial J Am Coll Cardiol. 2005;46(8):1417-24.

Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., Braunwald, E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial J Am Coll Cardiol. 2005;46(8):1405-10.

Reid, I. R., Tonkin, A., Cannon, C. P. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial Bone. 2005;37(2):190-1.

Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., Braunwald, E. C-reactive protein levels and outcomes after statin therapy N Engl J Med. 2005;352(1):20-8.

Ridker, P. M., Morrow, D. A., Rose, L. M., Rifai, N., Cannon, C. P., Braunwald, E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial J Am Coll Cardiol. 2005;45(10):1644-8.

Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., Braunwald, E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol. 2005;46(8):1411-6.

Ahmed, S., Cannon, C. P., Murphy, S. A., Braunwald, E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial Eur Heart J. 2006;27(19):2323-9.

Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., Braunwald, E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol. 2006;48(3):438-45. Abstract

Mega, J. L., Morrow, D. A., Cannon, C. P., Murphy, S., Cairns, R., Ridker, P. M., Braunwald, E. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy Journal of Thrombosis and Thrombolysis. 2006;22(1):71-76. Abstract

O'Donoghue, M., Morrow, D. A., Sabatine, M. S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial Circulation. 2006;113(14):1745-52.

Ray, K. K., Bach, R. G., Cannon, C. P., Cairns, R., Kirtane, A. J., Wiviott, S. D., McCabe, C. H., Braunwald, E., Gibson, C. M. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS Eur Heart J. 2006;27(19):2310-6.

Ray, K. K., Morrow, D. A., Shui, A., Rifai, N., Cannon, C. P. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22) Am J Cardiol. 2006;98(7):861-5. Abstract

Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, P., Shui, A., McCabe, C. H., Braunwald, E. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study J Am Coll Cardiol. 2006;47(11):2326-31.

Wiviott, S. D., de Lemos, J. A., Cannon, C. P., Blazing, M., Murphy, S. A., McCabe, C. H., Califf, R., Braunwald, E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22 Circulation. 2006;113(11):1406-14. Abstract

Murphy, S. A., Cannon, C. P., Wiviott, S. D., de Lemos, J. A., Blazing, M. A., McCabe, C. H., Califf, R. M., Braunwald, E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials) Am J Cardiol. 2007;100(7):1047-51. Abstract

Ray, K. K., Morrow, D. A., Sabatine, M. S., Shui, A., Rifai, N., Cannon, C. P., Braunwald, E. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome Circulation. 2007;115(24):3071-8.

Schreiner, G. C., Laine, L., Murphy, S. A., Cannon, C. P. Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed Crit Pathw Cardiol. 2007;6(4):169-72. Abstract

Brilakis, E. S., de Lemos, J. A., Cannon, C. P., Wiviott, S. D., Murphy, S. A., Morrow, D. A., Sabatine, M. S., Banerjee, S., Blazing, M. A., Califf, R. M., Braunwald, E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials) Am J Cardiol. 2008;102(5):552-8. Abstract

Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis J Am Coll Cardiol. 2008;52(11):914-20.

Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., Braunwald, E. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study J Am Coll Cardiol. 2008;51(4):449-55.

Lotfi, A., Schweiger, M. J., Giugliano, G. R., Murphy, S. A., Cannon, C. P. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis Am Heart J. 2008;155(5):954-8.

McLean, D. S., Ravid, S., Blazing, M., Gersh, B., Shui, A., Cannon, C. P. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials Am Heart J. 2008;155(2):298-302. Abstract

Miller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., Braunwald, E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol. 2008;51(7):724-30.

Morrow, D. A., Wang, Y., Croce, K., Sakuma, M., Sabatine, M. S., Gao, H., Pradhan, A. D., Healy, A. M., Buros, J., McCabe, C. H., Libby, P., Cannon, C. P., Braunwald, E., Simon, D. I. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial Am Heart J. 2008;155(1):49-55.

Gibson, C. M., Pride, Y. B., Hochberg, C. P., Sloan, S., Sabatine, M. S., Cannon, C. P. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy J Am Coll Cardiol. 2009;54(24):2290-5.

Mega, J. L., Morrow, D. A., Brown, A., Cannon, C. P., Sabatine, M. S. Identification of genetic variants associated with response to statin therapy Arteriosclerosis, thrombosis, and vascular biology. 2009;29(9):1310-5. Abstract

Murphy, S. A., Cannon, C. P., Wiviott, S. D., McCabe, C. H., Braunwald, E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial Journal of the American College of Cardiology. 2009;54(25):2358-62. Abstract

Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Ridker, P. M., Braunwald, E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arteriosclerosis, thrombosis, and vascular biology. 2009;29(3):424-30. Abstract

Scirica, B. M., Cannon, C. P., Sabatine, M. S., Jarolim, P., Sloane, S., Rifai, N., Braunwald, E., Morrow, D. A. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death Clin Chem. 2009;55(2):265-73.

Tung, P., Wiviott, S. D., Cannon, C. P., Murphy, S. A., McCabe, C. H., Gibson, C. M. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study) Am J Cardiol. 2009;103(8):1056-60.

Acharjee, S., Cannon, C. P. Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers Crit Pathw Cardiol. 2010;9(3):156-9. Abstract

Acharjee, S., Qin, J., Murphy, S. A., McCabe, C., Cannon, C. P. Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial) Am J Cardiol. 2010;105(5):619-23. Abstract

Bangalore, S., Qin, J., Sloan, S., Murphy, S. A., Cannon, C. P. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial Circulation. 2010;122(21):2142-51. Abstract

Khera, A. V., Wolfe, M. L., Cannon, C. P., Qin, J., Rader, D. J. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study) Am J Cardiol. 2010;106(4):451-6. Abstract

Ray, K. K., Nazer, B., Cairns, R., Michael Gibson, C., Cannon, C. P. Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes J Thromb Thrombolysis. 2010;30(1):3-Oct. Abstract

Bonaca, M. P., Morrow, D. A., Braunwald, E., Cannon, C. P., Jiang, S., Breher, S., Sabatine, M. S., Kempf, T., Wallentin, L., Wollert, K. C. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22 Arteriosclerosis, thrombosis, and vascular biology. 2011;31(1):203-10. Abstract

Li, Y., Sabatine, M. S., Tong, C. H., Ford, I., Kirchgessner, T. G., Packard, C. J., Robertson, M., Rowland, C. M., Bare, L. A., Shepherd, J., Devlin, J. J., Iakoubova, O. A. Genetic variants in the KIF6 region and coronary event reduction from statin therapy Hum Genet. 2011;129(1):17-23. Abstract

Nazer, B., Ray, K. K., Sloan, S., Scirica, B., Morrow, D. A., Cannon, C. P., Braunwald, E. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome European heart journal. 2011;32(11):1390-7. Abstract

Preiss, D., Seshasai, S. R., Welsh, P., Murphy, S. A., Ho, J. E., Waters, D. D., DeMicco, D. A., Barter, P., Cannon, C. P., Sabatine, M. S., Braunwald, E., Kastelein, J. J., de Lemos, J. A., Blazing, M. A., Pedersen, T. R., Tikkanen, M. J., Sattar, N., Ray, K. K. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA. 2011;305(24):2556-64. Abstract

Truong, Q. A., Murphy, S. A., McCabe, C. H., Armani, A., Cannon, C. P. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22 Circ Cardiovasc Qual Outcomes. 2011;4(3):328-36. Abstract

Wilson, S. R., Sabatine, M. S., Wiviott, S. D., Ray, K. K., De Lemos, J. A., Zhou, S., Rifai, N., Cannon, C. P., Morrow, D. A., Timi Study Group Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Am Heart J. 2011;161(6):1147-55 e1. Abstract

Braunwald, E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials European heart journal. 2012;33(4):430-2.

Bui, A. H., Bonaca, M. P., Sabatine, M. S., Ray, K. K., Rifai, N., Cannon, C. P., Morrow, D. A. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial J Thromb Thrombolysis. 2012;34(2):222-8. Abstract

Grandin, E. W., Jarolim, P., Murphy, S. A., Ritterova, L., Cannon, C. P., Braunwald, E., Morrow, D. A. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 Clinical chemistry. 2012;58(1):267-73. Abstract

Nazer, B., Ray, K. K., Murphy, S. A., Gibson, C. M., Cannon, C. P. Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy J Thromb Thrombolysis. 2013;36(3):233-9. Abstract

O'Donoghue, M., Morrow, D. A., Tsimikas, S., Sloan, S., Ren, A. F., Hoffman, E. B., Desai, N. P., Solomon, S. D., Domanski, M., Arai, K., Chiuve, S. E., Cannon, C. P., Sacks, F. M., Sabatine, M. S. Lipoprotein (a) For Risk Assessment in Patients with Established Coronary Artery Disease J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Sarma, A., Cannon, C. P., de Lemos, J., Rouleau, J. L., Lewis, E. F., Guo, J., Mega, J. L., Sabatine, M. S., O'Donoghue, M. L. The Incidence of Kidney Injury for Patients Treated With a High-Potency Versus Moderate-Potency Statin Regimen After an Acute Coronary Syndrome J Am Heart Assoc. 2014;3(3):e000784. Abstract